Trade Sanofi Adr Rep 1 1/2 - SNY CFD

Add to favourite

46.64

0.09%

View detailed chart

0.18

Low: 46.28

High: 46.8

Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon - Fri: 14:30 - 21:00

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow
Ownership

Trading Conditions

Spread

0.18

Long position overnight fee

-0.026235%

Short position overnight fee

0.004012%

Overnight fee time

22:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Sanofi SA ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	46.69
Open*	46.44
1-Year Change*	2.61%
Day's Range*	46.28 - 46.8
52 wk Range	42.63-57.82
Average Volume (10 days)	1.90M
Average Volume (3 months)	42.57M
Market Cap	118.06B
P/E Ratio	11.83
Shares Outstanding	1.25B
Revenue	49.85B
EPS	3.94
Dividend (Yield %)	4.08182
Beta	0.59
Next Earnings Date	Feb 1, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Nov 30, 2023	46.69	0.63	1.37%	46.06	46.71	45.84
Nov 29, 2023	46.38	-0.44	-0.94%	46.82	46.88	46.33
Nov 28, 2023	46.93	0.03	0.06%	46.90	47.29	46.85
Nov 27, 2023	47.60	0.07	0.15%	47.53	47.63	47.19
Nov 24, 2023	47.13	0.13	0.28%	47.00	47.24	46.97
Nov 22, 2023	46.37	0.07	0.15%	46.30	46.43	46.02
Nov 21, 2023	46.52	0.03	0.06%	46.49	46.80	46.42
Nov 20, 2023	46.43	-0.07	-0.15%	46.50	46.88	46.43
Nov 17, 2023	46.94	0.26	0.56%	46.68	46.95	46.45
Nov 16, 2023	46.27	0.32	0.70%	45.95	46.30	45.85
Nov 15, 2023	45.36	0.08	0.18%	45.28	46.05	45.05
Nov 14, 2023	45.66	0.05	0.11%	45.61	46.00	45.50
Nov 13, 2023	45.44	0.15	0.33%	45.29	45.60	45.07
Nov 10, 2023	45.86	-0.19	-0.41%	46.05	46.06	44.97
Nov 9, 2023	45.43	-0.71	-1.54%	46.14	46.15	45.31
Nov 8, 2023	45.71	-0.05	-0.11%	45.76	46.18	45.56
Nov 7, 2023	45.20	0.17	0.38%	45.03	45.36	44.94
Nov 6, 2023	45.17	-0.44	-0.96%	45.61	45.74	45.03
Nov 3, 2023	45.74	0.23	0.51%	45.51	46.09	45.15
Nov 2, 2023	46.45	-0.45	-0.96%	46.90	47.03	46.11

Sanofi Adr Rep 1 1/2 Events

Time (UTC)	Country	Event
No events scheduled

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	45389	39175	37369	37631	35677
Revenue	45389	39175	37369	37631	35677
Cost of Revenue, Total	13695	12255	12159	11979	11435
Gross Profit	31694	26920	25210	25652	24242
Total Operating Expense	34733	31049	23256	34580	31001
Selling/General/Admin. Expenses, Total	10410	9457	9304	9777	9772
Research & Development	6705	5689	5528	6017	5890
Depreciation / Amortization	2140	1681	1774	2262	2264
Unusual Expense (Income)	-581	235	777	3966	1696
Other Operating Expenses, Total	2391	1728	1220	817	61
Operating Income	10656	8126	14113	3051	4676
Interest Income (Expense), Net Non-Operating	-167	-289	-263	-210	-273
Other, Net	-67	-39	-72	-89	2
Net Income Before Taxes	10422	7798	13778	2752	4405
Net Income After Taxes	8416	6240	11971	2631	3924
Minority Interest	-113	-56	-36	-31	-104
Equity In Affiliates	68	39	359	255	499
Net Income Before Extra. Items	8371	6223	12294	2855	4319
Total Extraordinary Items		0	0	-101	-13
Net Income	8371	6223	12294	2754	4306
Income Available to Common Excl. Extra. Items	8371	6223	12294	2855	4319
Income Available to Common Incl. Extra. Items	8371	6223	12294	2754	4306
Diluted Net Income	8371	6223	12294	2754	4306
Diluted Weighted Average Shares	1256.9	1257.9	1260.1	1257.1	1255.2
Diluted EPS Excluding Extraordinary Items	6.66004	4.94713	9.75637	2.2711	3.44089
Dividends per Share - Common Stock Primary Issue	3.56	3.31263	3.2	3.15	3.07
Diluted Normalized EPS	5.79655	5.09663	10.2921	5.28727	4.64452
Interest Expense (Income) - Net Operating	-27	4	-7506	-238	-117

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	21545	10863	24594	13138	20795
Revenue	21545	10863	24594	13138	20795
Cost of Revenue, Total	6347	3079	7565	3831	6130
Gross Profit	15198	7784	17029	9307	14665
Total Operating Expense	17223	8400	17767	10414	16966
Selling/General/Admin. Expenses, Total	5182	2607	5539	2644	4953
Research & Development	3193	1563	3559	1736	3147
Depreciation / Amortization	1035	489	1143	460	910
Unusual Expense (Income)	635	343	231	1955	1021
Other Operating Expenses, Total	805	304	-226	-180	788
Operating Income	4322	2463	6827	2724	3829
Interest Income (Expense), Net Non-Operating	4	-7	-62	-51	-135
Net Income Before Taxes	4238	2456	6748	2673	3674
Net Income After Taxes	3508	1997	5237	2072	3179
Minority Interest	-26	-14	-60	-3	-53
Equity In Affiliates	-52	12	10	7	58
Net Income Before Extra. Items	3430	1995	5187	2076	3184
Net Income	3430	1995	5187	2076	3184
Income Available to Common Excl. Extra. Items	3430	1995	5187	2076	3184
Income Available to Common Incl. Extra. Items	3430	1995	5187	2076	3184
Diluted Net Income	3430	1995	5187	2076	3184
Diluted Weighted Average Shares	1254.5	1249.3	1258.5	1253.5	1255.3
Diluted EPS Excluding Extraordinary Items	2.73416	1.59689	4.12157	1.65616	2.53645
Dividends per Share - Common Stock Primary Issue	0	0	3.56	0	0
Diluted Normalized EPS	3.15315	1.82014	4.26402	2.86513	3.24021
Interest Expense (Income) - Net Operating	26	15	-44	-32	17
Other, Net	-88		-17		-20
Total Extraordinary Items

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	34026	30564	33703	28611	24579
Cash and Short Term Investments	13400	11152	14815	9853	7124
Cash	1385	1358	1144	701	661
Cash & Equivalents	11351	8740	12771	8726	6264
Short Term Investments	664	1054	900	426	199
Total Receivables, Net	10746	9787	9953	10083	9345
Accounts Receivable - Trade, Net	8424	7568	7491	7937	7260
Total Inventory	8960	8715	8352	7994	7477
Prepaid Expenses	714	615	525	493	469
Other Current Assets, Total	206	295	58	188	164
Total Assets	126722	120242	114413	112630	111408
Property/Plant/Equipment, Total - Net	11684	11976	10563	11017	9651
Property/Plant/Equipment, Total - Gross	26796	27555	24880	25151	22697
Accumulated Depreciation, Total	-15112	-15579	-14317	-14134	-13046
Goodwill, Net	49892	48056	44364	44519	44235
Intangibles, Net	21640	21407	18341	16509	21889
Long Term Investments	2765	2425	2129	5303	5550
Note Receivable - Long Term	452	485	537	521	746
Other Long Term Assets, Total	6263	5329	4776	6150	4758
Total Current Liabilities	23964	21295	19248	20381	17376
Accounts Payable	6813	6180	5295	5313	5041
Accrued Expenses	2158	2126	2042	1978	1989
Notes Payable/Short Term Debt	168	189	285	305	249
Current Port. of LT Debt/Capital Leases	4287	3263	2714	4508	2364
Other Current Liabilities, Total	10538	9537	8912	8277	7733
Total Liabilities	51938	51561	51307	53574	52532
Total Long Term Debt	16761	18962	20676	21118	22071
Long Term Debt	14857	17123	19745	20131	22053
Capital Lease Obligations	1904	1839	931	987	18
Deferred Income Tax	1841	1617	1770	2294	3414
Minority Interest	368	350	146	174	159
Other Liabilities, Total	9004	9337	9467	9607	9512
Total Equity	74784	68681	63106	59056	58876
Common Stock	2522	2527	2518	2508	2495
Additional Paid-In Capital	66859	63545	60511	52049	53106
Treasury Stock - Common	-706	-939	-705	-9	-153
Other Equity, Total	6109	3548	782	4508	3428
Total Liabilities & Shareholders’ Equity	126722	120242	114413	112630	111408
Total Common Shares Outstanding	1252.64	1252.54	1250.69	1253.83	1245.45

	Jun 2023	Dec 2022
Total Current Assets	29976	34026
Cash and Short Term Investments	7993	12736
Cash & Equivalents	7993	12736
Total Receivables, Net	8642	8798
Accounts Receivable - Trade, Net	8289	8424
Total Inventory	9970	8960
Other Current Assets, Total	3371	3532
Total Assets	125353	126722
Property/Plant/Equipment, Total - Net	11527	11684
Goodwill, Net	49243	49892
Intangibles, Net	24590	21640
Long Term Investments	2550	2765
Note Receivable - Long Term	447	452
Other Long Term Assets, Total	7020	6263
Total Current Liabilities	24760	23964
Accounts Payable	7365	6813
Notes Payable/Short Term Debt	133	168
Current Port. of LT Debt/Capital Leases	4780	4287
Other Current Liabilities, Total	12482	12696
Total Liabilities	52724	51938
Total Long Term Debt	16080	16761
Long Term Debt	14241	14857
Capital Lease Obligations	1839	1904
Deferred Income Tax	1950	1841
Minority Interest	318	368
Other Liabilities, Total	9616	9004
Total Equity	72629	74784
Common Stock	2525	2522
Additional Paid-In Capital	140	66859
Retained Earnings (Accumulated Deficit)	65694
Treasury Stock - Common	-957	-706
Other Equity, Total	5227	6109
Total Liabilities & Shareholders’ Equity	125353	126722
Total Common Shares Outstanding	1251.49	1252.64

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	8371	6223	12294	2754	4306
Cash From Operating Activities	10526	10522	7418	7715	5547
Cash From Operating Activities	3420	3351	3671	7445	4279
Deferred Taxes	-578	-356	-221	-1772	-727
Non-Cash Items	20	-105	-8001	-293	-1031
Cash Taxes Paid	2452	1280	2051	1695	2058
Cash Interest Paid	380	334	315	379	412
Changes in Working Capital	-707	1409	-325	-419	-1280
Cash From Investing Activities	-2075	-7298	3619	-1029	-12872
Capital Expenditures	-2201	-2043	-2083	-1787	-1977
Other Investing Cash Flow Items, Total	126	-5255	5702	758	-10895
Cash From Financing Activities	-5821	-7056	-6485	-4193	3934
Financing Cash Flow Items	-99	-48	-44	-21	-91
Total Cash Dividends Paid	-4168	-4008	-3937	-3834	-3773
Issuance (Retirement) of Stock, Net	-309	-196	-619	153	-924
Issuance (Retirement) of Debt, Net	-1245	-2804	-1885	-491	8722
Foreign Exchange Effects	8	15	-64	9	1
Net Change in Cash	2638	-3817	4488	2502	-3390

	Dec 2022	Jun 2022
Net income/Starting Line	8371	3184
Cash From Operating Activities	10526	3825
Cash From Operating Activities	3420	1820
Deferred Taxes	-578	-404
Non-Cash Items	20	267
Cash Taxes Paid	2452	927
Cash Interest Paid	380	162
Changes in Working Capital	-707	-1042
Cash From Investing Activities	-2075	-1459
Capital Expenditures	-2201	-974
Other Investing Cash Flow Items, Total	126	-485
Cash From Financing Activities	-5821	-5605
Financing Cash Flow Items	-99	-69
Total Cash Dividends Paid	-4168	-4168
Issuance (Retirement) of Stock, Net	-309	-320
Issuance (Retirement) of Debt, Net	-1245	-1048
Foreign Exchange Effects	8	40
Net Change in Cash	2638	-3199

Investor Name	Investor Type	Percent Outstanding	Shares Held	Shares change	Holdings Date	Turnover Rating
Dodge & Cox	Investment Advisor/Hedge Fund	3.1884	80500374	-2016952	2023-06-30	LOW
Fidelity Management & Research Company LLC	Investment Advisor	0.7738	19536035	-666346	2023-06-30	LOW
Boston Partners	Investment Advisor/Hedge Fund	0.5194	13114702	-4831241	2023-06-30	LOW
Fisher Investments	Investment Advisor/Hedge Fund	0.5132	12956823	-402706	2023-06-30	LOW
Managed Account Advisors LLC	Investment Advisor	0.2902	7328135	70778	2023-06-30	LOW
Invesco Advisers, Inc.	Investment Advisor	0.2426	6125523	329525	2023-06-30	LOW
BlackRock Investment Management, LLC	Investment Advisor/Hedge Fund	0.22	5554305	-366015	2023-06-30	LOW
Camber Capital Management LP	Hedge Fund	0.1584	4000000	-1500000	2023-06-30	MED
Parametric Portfolio Associates LLC	Investment Advisor	0.1413	3567583	91095	2023-06-30	LOW
Fidelity Institutional Asset Management	Investment Advisor	0.1273	3213122	133302	2023-06-30	LOW
BofA Global Research (US)	Research Firm	0.1233	3112755	-256827	2023-06-30	LOW
Federated Hermes Investment Counseling	Investment Advisor/Hedge Fund	0.1017	2568436	466805	2023-06-30	MED
Hotchkis and Wiley Capital Management, LLC	Investment Advisor	0.0935	2361025	-12900	2023-06-30	LOW
Wells Fargo Advisors	Research Firm	0.0911	2299130	185816	2023-06-30	LOW
Envestnet Asset Management, Inc.	Investment Advisor	0.0866	2187147	804620	2023-06-30	LOW
Ostrum Asset Management	Investment Advisor	0.0864	2181726	194439	2023-06-30	MED
Newton Investment Management North America, LLC	Investment Advisor	0.0838	2116558	-1002724	2023-09-30	MED
Raymond James & Associates, Inc.	Research Firm	0.083	2096142	31773	2023-09-30	LOW
Equity Investment Corporation	Investment Advisor	0.0772	1948154	-60294	2023-06-30	LOW
BNY Mellon Wealth Management	Investment Advisor/Hedge Fund	0.077	1943068	52655	2023-09-30	LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Sanofi Company profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The company’s segments are Pharmaceuticals, Human Vaccines, and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the company’s pharmaceuticals operations. The Pharmaceuticals segment also includes all associates whose activities are related to pharmaceuticals. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the company’s vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the company’s vaccines operations. Follow Capital.com to keep up with Sanofi (SNY) share price.

Industry:

Pharmaceuticals (NEC)

46 Avenue de la Grande Armée
PARIS
ILE-DE-FRANCE 75017
FR

Income Statement

Annual
Quarterly

News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023